SELLAS Life Sciences' GPS vaccine demonstrated a 41% reduction in death risk and nine-month survival benefit in a pivotal Phase 3 AML trial, sending shares up 220%.
A Nature study using serial blood samples shows the first driver mutations for acute myeloid leukaemia typically arise in the first few decades of life, with later mutations driving 100-fold larger selective advantages and complete blood sweeps decades before diagnosis.